Kluwer Patent Blog

Germany: Raltegravir, Federal Court of Justice of Germany, X ZB 2/17, 11 July 2017

Jochen Buehling (Krieger Mes Graf & v. der Groeben) · Tuesday, October 24th, 2017

In this case the Federal Court of Justice (FCJ) allowed a compulsory licence under a patent for a pharmaceutical active ingredient for the first time ever. The Court held that a public interest in such a licence may still exist where it concerns only a small group of patients. In particular, the interest may be established if the specific patient group would otherwise be exposed to an extremely high risk if the medicament were no longer available. Whether the petitioner seeking a compulsory licence has made sufficient efforts to obtain a licence from the patentee on reasonable, commonly accepted conditions must be assessed in light of the circumstances of the specific individual case.

A full summary of this case has been published on Kluwer IP Law

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?


Learn how Kluwer IP Law can support you.

1

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Tuesday, October 24th, 2017 at 12:42 am and is filed under (Compulsory) license, Case Law, Germany

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.